Table 1.

Mutation rate ofA/Mallard/New York/6750/78

Clone no.Plaque inhibition assay result (PFU/ml)Allantoic fluid (ml)Population size (PFU)aMutant frequencybMutation rate (bp/site/replication)cQuotient (control/ amantadine)Quotient × 4Quotient × 4/ genome length
ControlAmantadine
11.6 × 107 1.2 × 104 7.01.1 × 108 7.5 × 10−4 1.4 × 10−5 1.3 × 103 5.3 × 103 0.4
24.0 × 107 3.2 × 104 9.13.6 × 108 8.0 × 10−4 1.4 × 10−5 1.3 × 103 5.0 × 103 0.4
31.0 × 107 1.2 × 104 7.17.1 × 107 1.2 × 10−3 2.3 × 10−5 8.3 × 102 3.3 × 103 0.2
42.9 × 107 1.2 × 104 7.82.3 × 108 4.1 × 10−4 7.5 × 10−6 2.4 × 103 9.7 × 103 0.7
52.0 × 107 4.4 × 104 8.51.7 × 108 2.2 × 10−3 4.0 × 10−5 4.5 × 102 1.8 × 103 0.1
69.6 × 106 1.6 × 104 13.31.3 × 108 1.7 × 10−3 3.1 × 10−5 6.0 × 102 2.4 × 103 0.2
76.8 × 107 8.0 × 103 9.36.3 × 108 1.2 × 10−4 2.0 × 10−6 8.5 × 103 3.4 × 104 2.5
88.4 × 107 4.0 × 104 10.48.7 × 108 4.8 × 10−4 8.0 × 10−6 2.1 × 103 8.4 × 103 0.6
93.2 × 107 3.2 × 105 7.92.5 × 108 1.0 × 10−2 1.8 × 10−4 1.0 × 102 4.0 × 102 0.0
101.1 × 108 4.0 × 103 13.61.5 × 109 3.6 × 10−5 6.0 × 10−7 2.8 × 104 1.1 × 105 8.1
Average4.2 × 107 5.0 × 104 4.3 × 108 1.8 × 10−3 3.2 × 10−5 4.5 × 103 1.8 × 104 1.3
  • a Product of titer from control and amount of allantoic fluid.

  • b Quotient of titers from plaque inhibition assays with amantadine and control.

  • c Rate for each clone calculated from mutant frequency and population size as described in Materials and Methods.